Seed Wealth Management Inc. Sells 280 Shares of CVS Health Co. (NYSE:CVS)

Seed Wealth Management Inc. trimmed its position in CVS Health Co. (NYSE:CVS) by 8.4% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 3,055 shares of the pharmacy operator’s stock after selling 280 shares during the period. Seed Wealth Management Inc.’s holdings in CVS Health were worth $243,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in CVS Health by 0.4% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 202,838 shares of the pharmacy operator’s stock valued at $16,178,000 after buying an additional 823 shares during the period. Janiczek Wealth Management LLC boosted its position in shares of CVS Health by 38.6% in the 1st quarter. Janiczek Wealth Management LLC now owns 1,755 shares of the pharmacy operator’s stock worth $140,000 after purchasing an additional 489 shares during the last quarter. Exeter Financial LLC grew its stake in shares of CVS Health by 0.7% during the first quarter. Exeter Financial LLC now owns 32,924 shares of the pharmacy operator’s stock worth $2,433,000 after purchasing an additional 225 shares during the period. St. Johns Investment Management Company LLC increased its holdings in CVS Health by 37.8% in the first quarter. St. Johns Investment Management Company LLC now owns 17,799 shares of the pharmacy operator’s stock valued at $1,420,000 after purchasing an additional 4,878 shares during the last quarter. Finally, Brookstone Capital Management lifted its stake in CVS Health by 3.3% in the first quarter. Brookstone Capital Management now owns 65,157 shares of the pharmacy operator’s stock valued at $5,197,000 after buying an additional 2,054 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 3.7 %

CVS traded down $2.27 on Thursday, hitting $58.37. 16,221,576 shares of the company were exchanged, compared to its average volume of 12,083,041. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. The stock’s fifty day moving average is $60.00 and its 200-day moving average is $70.38. The company has a market cap of $73.27 billion, a PE ratio of 10.22, a PEG ratio of 0.58 and a beta of 0.53. CVS Health Co. has a 12 month low of $52.77 and a 12 month high of $83.25.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing the consensus estimate of $1.69 by ($0.38). CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The company had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. During the same quarter in the prior year, the firm earned $2.20 earnings per share. CVS Health’s revenue for the quarter was up 3.7% on a year-over-year basis. Equities research analysts predict that CVS Health Co. will post 7.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other CVS Health news, Director Edward J. Ludwig purchased 1,000 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was purchased at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the transaction, the director now owns 21,630 shares in the company, valued at approximately $1,165,424.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on CVS shares. Barclays lowered their price target on CVS Health from $78.00 to $63.00 and set an “equal weight” rating for the company in a research note on Thursday, May 2nd. Argus cut their target price on shares of CVS Health from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. SVB Leerink reissued a “market perform” rating and issued a $60.00 price target (down previously from $87.00) on shares of CVS Health in a report on Wednesday, May 1st. UBS Group cut CVS Health from a “buy” rating to a “neutral” rating and decreased their target price for the company from $85.00 to $60.00 in a research note on Thursday, May 2nd. Finally, Mizuho dropped their price target on CVS Health from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $75.05.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.